Genetic test may guide chemo choice for pancreatic cancer patients
NCT ID NCT07616362
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see if personalized chemo improves event-free survival and increases the chance of successful surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (nab-paclitaxel/gemcitabine or mFOLFIRINOX)
What this could lead to
If successful, this could show that using a genetic signature to choose chemotherapy improves survival and surgery rates for people with borderline resectable pancreatic cancer.
What could go wrong
This is a phase II trial with only 110 participants, so results are preliminary. The genetic test may not reliably predict which chemo works best, and both regimens have significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopital Nord Chu Saint Etienne
Saint-Priest-en-Jarez, France
Contact Email: •••••@•••••
Contact
-
Hôpital Beaujon
Clichy, France
Contact
Contact Email: •••••@•••••
-
Hôpital Lyon Sud
Pierre-Bénite, France
Contact
Contact Email: •••••@•••••
-
Hôpital Rangueil
Toulouse, France
Contact Email: •••••@•••••
Contact
-
Institut Paoli Calmettes
Marseille, France
Contact
Contact Email: •••••@•••••